Nimorazole is a hypoxic modifier and radiosensitizer that exhibits anticancer and anti-parasitic activities. Nimorazole is clinically used to treat trichomoniasis. Nimorazole features a structure similar to that of other nitroimidazole antimicrobial compounds.
| Cas No. | 6506-37-2 |
|---|---|
| Purity | ≥98% |
| Formula | C9H14N4O3 |
| Formula Wt. | 226.24 |
| IUPAC Name | 4-[2-(5-Nitro-1H-imidazol-1-yl)ethyl]morpholine |
| Synonym | K 1900, K-1900, K1900, NSC 107524, NSC-107524, NSC107524 |
| Solubility | 10 mM in DMSO |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Metwally MA, Frederiksen KD, Overgaard J. Compliance and toxicity of the hypoxic radiosensitizer nimorazole in the treatment of patients with head and neck squamous cell carcinoma (HNSCC). Acta Oncol. 2014 May;53(5):654-61. PMID: 24328536.
Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10-11):509-18. PMID: 7620219.
Overgaard J, Overgaard M, Nielsen OS, et al. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo. Br J Cancer. 1982 Dec;46(6):904-11. PMID: 7150484.
Wigfield AS. Trichomonal vaginitis. A 24-hr regimen of nimorazole compared with a 7-day regimen of metronidazole. Br J Vener Dis. 1975 Feb;51(1):54-6. PMID: 1092425.
